---
schema_version: "secwatch.filing_event.v1"
accession: "0000875320-25-000230"
form_type: "8-K"
ticker: "VRTX"
cik: "0000875320"
company_name: "VERTEX PHARMACEUTICALS INC / MA"
filed_at: "2025-11-03T23:59:59+00:00"
generated_at: "2026-05-17T01:01:50.146792+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Vertex Q3 rev $3.08B (+11% YoY), FY guidance refined; povetacicept IgAN BLA on track

## Summary
- Q3 total revenue $3.08B (+11% vs Q3 2024); GAAP net income $1.1B, non-GAAP $1.2B.
- FY2025 revenue guidance raised to $11.9-12.0B; non-GAAP OpEx guidance $5.0-5.1B; tax rate lowered to 17-18%.
- Povetacicept Phase 3 IgAN enrollment complete; first BLA module submission to FDA by end of 2025.
- JOURNAVX: >300K prescriptions since March; CASGEVY: 165 cell collections, 39 infusions globally.
- Zimislecel T1D trial enrollment complete; dosing temporarily postponed pending manufacturing analysis.

## SEC filing metadata
- accession: 0000875320-25-000230
- form_type: 8-K
- ticker: VRTX
- cik: 0000875320
- company_name: VERTEX PHARMACEUTICALS INC / MA
- filed_at: 2025-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/875320/000087532025000230/0000875320-25-000230-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/875320/000087532025000230/vrtx-20251103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000875320-25-000230
- JSON: https://secwatch.observer/filing/0000875320-25-000230.json
- Plain text: https://secwatch.observer/filing/0000875320-25-000230.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.